Valuation: Orthocell Limited

Market Cap 197M 138M 120M 111M 102M 193M 13.26B 1.33B 522M 6.5B 517M 506M 22.38B P/E 2026 *
-18.1x
P/E 2027 * -36.3x
Enterprise Value 157M 109M 95.61M 88.21M 81.24M 153M 10.53B 1.05B 415M 5.16B 411M 402M 17.77B EV / Sales 2026 *
13.7x
EV / Sales 2027 * 7.79x
Free-Float
83.36%
Yield 2026 *
-
Yield 2027 * -
1 day-2.68%
1 week-13.17%
1 month-5.84%
3 months-28.92%
6 months-27.50%
Current year-33.18%
1 week 0.72
Extreme 0.725
0.91
1 month 0.7
Extreme 0.7
0.91
Current year 0.7
Extreme 0.7
1.16
1 year 0.7
Extreme 0.7
1.6
3 years 0.32
Extreme 0.322
1.79
5 years 0.3
Extreme 0.3
1.79
10 years 0.1
Extreme 0.105
1.79
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer - 21/03/2006
Chief Executive Officer 60 21/03/2006
Director of Finance/CFO - 01/08/2025
Director TitleAgeSince
Director/Board Member - 01/11/2023
Chairman - 01/06/2023
Director/Board Member 60 08/03/2023
Date Insider Type Main position Quantity % Market Cap.
03/05/26 Buy 23,615 0.0087%
01/05/26 Buy

Chairman

25,000 0.0092%
25/02/26 Buy

Chairman

32,500 0.0120%
Change 5-day change 1-year change 3-year change Capi.($)
-2.68%-13.17%-41.06%+85.90% 142M
-1.97%+1.48%+27.90%+0.59% 202B
-0.58%+4.01%+5.45%-15.26% 145B
-14.15%-16.07%-32.62%-2.42% 142B
-1.32%-2.13%-57.33%-16.97% 66.32B
-2.40%-6.13%+12.60%-8.19% 50.58B
-0.11%+2.15%-23.83%-32.04% 44.81B
-3.41%-1.59%+15.90%+9.78% 38.44B
-2.44%-2.16%+27.43%+36.27% 37.13B
-4.00%-2.52%-16.41%-22.92% 29.89B
Average -1.80%-0.06%-8.20%+3.47% 75.68B
Weighted average by Cap. -1.28%+1.83%-1.75%-5.77%

Financials

2026 *2027 *
Net sales 11.45M 7.99M 6.99M 6.45M 5.94M 11.2M 769M 77.08M 30.3M 377M 30.01M 29.35M 1.3B 21.55M 15.04M 13.15M 12.13M 11.17M 21.08M 1.45B 145M 57.04M 710M 56.49M 55.24M 2.44B
Net income -12.7M -8.86M -7.75M -7.15M -6.58M -12.42M -853M -85.5M -33.61M -418M -33.29M -32.56M -1.44B -8.55M -5.97M -5.22M -4.81M -4.43M -8.36M -575M -57.56M -22.63M -282M -22.41M -21.92M -969M
Net Debt -40.7M -28.41M -24.84M -22.91M -21.1M -39.8M -2.73B -274M -108M -1.34B -107M -104M -4.61B -29.5M -20.59M -18M -16.61M -15.3M -28.85M -1.98B -199M -78.08M -971M -77.33M -75.62M -3.34B
Logo Orthocell Limited
Orthocell Limited is an Australia-based regenerative medicine company. The Company is focused on regenerating mobility for patients by developing products for the repair of a variety of bone and soft tissue injuries. Its portfolio of products includes Striate+, Remplir, and OrthoACI. Striate+ is an acellular resorbable collagen membrane used for guided bone and tissue regeneration in dental applications. Remplir is a collagen-based nerve wrap designed to support nerve repair surgery in peripheral nerve repair. OrthoACI, or Autologous Chondrocyte Implantation, offers treatment for symptomatic defects of the articulating cartilage of the joints. OrthoACI uses the patient’s own healthy cartilage cells called chondrocytes to assist the regeneration of damaged cartilage. The Company is engaged in the development of its tendon cell therapy in the United States. Its autologous tendon therapy is an advanced injectable cellular therapy for the treatment of chronic tendon injuries.
Employees
-
Date Price Change Volume
17/07/26 A$0.7250 -2.68% 189,537
16/07/26 A$0.7450 -1.97% 391,292
15/07/26 A$0.7600 -4.40% 644,677
14/07/26 A$0.7950 -6.47% 426,344
13/07/26 A$0.8500 +0.59% 1,573,072
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.7250AUD
Average target price
1.225AUD
Spread / Average Target
+68.97%

Quarterly revenue - Rate of surprise